Pharmaceutical - Hematology

Filter

Current filters:

Hematology

Popular Filters

1 to 25 of 58 results

TG Therapeutics takes up option on PI3K-Delta inhibitor, TGR-1202

23-09-2014

US development stage company TG Therapeutics says it has exercised its option to license the global rights…

HematologyLicensingOncologyPharmaceuticalRhizen PharmaceuticalsTG TherapeuticsTGR-1202

Vifor appoints Dario Eklund head of international business and Abdul Mullick head of global marketing

Vifor appoints Dario Eklund head of international business and Abdul Mullick head of global marketing

19-09-2014

Swiss-based iron deficiency specialist Vifor Pharma has appointed Dario Eklund as head of international…

BoardroomHematologyPharmaceuticalSwitzerlandVifor Pharma

FDA backs added indication for GSK’s Promacta

FDA backs added indication for GSK’s Promacta

27-08-2014

The Food and Drug Administration has approved UK pharma giant GlaxoSmithKline’s supplemental New Drug…

GlaxoSmithKlineHematologyLigand PharmaceuticalsPharmaceuticalPromactaRare diseasesRegulationRevoladeUSA

Positive top-line Ph III results for Baxter’s BAX 855 in hemophilia A

Positive top-line Ph III results for Baxter’s BAX 855 in hemophilia A

21-08-2014

US drugmaker Baxter International has announced positive results from its Phase III pivotal clinical…

AdvateBAX 855Baxter InternationalHematologyPharmaceuticalRegulationResearch

Kyowa Hakko Kirin files for KW-3357 approval in Japan

Kyowa Hakko Kirin files for KW-3357 approval in Japan

01-08-2014

Japanese drugmaker Kyowa Hakko Kirin has filed an application for marketing approval with the Ministry…

HematologyJapanKW-3357Kyowa Hakko KirinPharmaceuticalRare diseasesRegulationThrombus

BMJ alleges Boehringer Ingelheim withheld Pradaxa dosing information from regulators

BMJ alleges Boehringer Ingelheim withheld Pradaxa dosing information from regulators

24-07-2014

German family-owned drug major Boehringer Ingelheim has been accused of withholding ‘important analyses’…

Boehringer IngelheimDabigatranGermanyHematologyPharmaceuticalPradaxaPyridinesRegulationUKUniversity of California

Pfizer’s BeneFIX reduces bleeding rates in Ph III study

Pfizer’s BeneFIX reduces bleeding rates in Ph III study

16-07-2014

US pharma giant Pfizer today released positive results of a Phase III study comparing a prophylaxis regimen…

BenefixHaemophiliaHematologyHemophilia BPfizerPharmaceuticalResearchSevere hemophilia BUSA

Bayer the latest in anticoagulant lawsuit action

Bayer the latest in anticoagulant lawsuit action

16-07-2014

German drug major Bayer is just one of the latest companies to be facing lawsuits over its anticoagulants,…

BayerBoehringer IngelheimHematologyHematologyLegalPharmaceuticalPradaxaRivaroxabanUSAWarfarin SodiumXarelto

Boehringer Ingelheim’s Pradaxa available in UK for DVT

Boehringer Ingelheim’s Pradaxa available in UK for DVT

15-07-2014

German family-owned drug major Boehringer Ingelheim says that Pradaxa (dabigatran etexilate) will be…

Boehringer IngelheimDeep vein thrombosisHematologyPharmaceuticalPradaxaRegulationUK

EU orphan designations for OPKO's clotting Factor VIIa-CTP

EU orphan designations for OPKO's clotting Factor VIIa-CTP

10-07-2014

The European Committee for Orphan Medicinal Products (COMP) gave a positive opinion recommending the…

EuropeFactor VIIa-CTPHematologyOPKO HealthPharmaceuticalRare diseasesRegulation

Novo Nordisk gains FDA backing for new NovoSeven RT indication

Novo Nordisk gains FDA backing for new NovoSeven RT indication

09-07-2014

Danish diabetes care giant Novo Nordisk’s hemophilia treatment NovoSeven RT (coagulation factor VIIa…

HematologyNovo NordiskNovoSevenNovoSeven RTPharmaceuticalRare diseasesRegulationUSA

JAMA study shows bone marrow transplants can reverse sickle cell disease

03-07-2014

Bone marrow transplants can reverse severe sickle cell disease in adults, according to new data published…

HematologyPharmaceuticalResearchUSA

EHA 2014: Velcade combination shows high efficacy in Mantle Cell Lymphoma

EHA 2014: Velcade combination shows high efficacy in Mantle Cell Lymphoma

16-06-2014

Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson, announced Phase…

EuropeHematologyJanssen-CilagLymphomaPharmaceuticalResearchVelcade

EHA 2014: Celgene announces results on Pomalyst, Vidaza and beta-thalassemia collaboration

EHA 2014: Celgene announces results on Pomalyst, Vidaza and beta-thalassemia collaboration

16-06-2014

Among companies presenting results from across the board at the European Hematology Association annual…

Beta-thalassemiaCelgeneEuropeHematologyPharmaceuticalpomalidomideResearchVidaza

Vifor’s Ferinject reduces need for other anemia treatment

03-06-2014

Vifor Pharma, a part of Switzerland-based Galenica Group which develops pharmaceutical products for the…

EuropeFerinjectHematologyPharmaceuticalResearchVifor Pharma

FDA approves new indication for Bayer's Kogenate

12-05-2014

The US Food and Drug Administration has approved a new indication for German drug major Bayer's Kogenate…

BayerHematologyKogenate FSPharmaceuticalRegulationUSA

IQWiG finds added benefit for Novo Nordisk’s NovoEight not proven

23-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyHematologyNorthern EuropeNovo NordiskNovoEightPharmaceuticalPricingRegulation

Baxter’s BAX 111 meets Ph III primary efficacy endpoint for VWF patients

Baxter’s BAX 111 meets Ph III primary efficacy endpoint for VWF patients

17-04-2014

US health care company Baxter International as released encouraging top-line results from a Phase III…

BAX 111Baxter InternationalHematologyPharmaceuticalResearch

Health Canada approves Biogen Idec’s long-acting Alprolix hemophilia B

Health Canada approves Biogen Idec’s long-acting Alprolix hemophilia B

21-03-2014

US biotech firm Biogen Idec has announced that Health Canada has approved Alprolix for the control and…

AlprolixBiogen IdecCanadaHematologyPharmaceuticalRegulation

1 to 25 of 58 results

Back to top